ZIOPHARM Oncology (NASDAQ:ZIOP)

CAPS Rating: 2 out of 5

Results 1 - 6 of 6

Recs

0
Member Avatar Aurum (61.71) Submitted: 7/29/2014 12:47:10 PM : Outperform Start Price: $3.26 ZIOP Score: +0.67

Part of a broader pick of micro cap biotechs with encouraging preliminary clinical trial data and significant upside.

Recs

0
Member Avatar MystereX (64.00) Submitted: 11/1/2013 1:39:54 PM : Outperform Start Price: $3.55 ZIOP Score: -20.19

Ad-RST-IL-12 UPDATE

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 9/26/2013 5:35:43 AM : Outperform Start Price: $3.20 ZIOP Score: -14.46

monthly IHS

Recs

0
Member Avatar Ezquire65 (39.75) Submitted: 5/22/2012 2:57:23 PM : Outperform Start Price: $4.74 ZIOP Score: -68.48

A true speculative play with huge upside potential. With master investory RJ Kirk behind this security and from all accounts many promising developments. This could be the proverbial 5 bagger holy grail that FOOLS rarely see.

Recs

1
Member Avatar mavrant (< 20) Submitted: 6/2/2011 12:36:29 PM : Outperform Start Price: $6.74 ZIOP Score: -101.67

possible new technology

Recs

1
Member Avatar AGCAPS1 (37.81) Submitted: 1/26/2011 10:19:00 AM : Underperform Start Price: $5.98 ZIOP Score: +97.23

First review the released statements since 2009. Then read about what this company does. They research on eliminations of the existent cancer drugs side effects. This company works in drugs researching provided by Intrexon. If they become successful “many years away”, most likely the Intrexon will be the one profit from it. The stock is overpriced.

Results 1 - 6 of 6

Featured Broker Partners


Advertisement